ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
4Q 2023 Preliminary Unaudited Total Revenue of $72-74 Million FY 2023 Preliminary Unaudited Total Revenue of $256-258 Million FY 2024 and 2025 Total Revenue Guidance Increased to More than $320...
Source: marketscreener.com